Roscrea biopharma firm secures $100m investment ahead of plans for IPO
The Tipperary-based company aims to list on the US stock market within the coming months and believes its new drug candidates are worth at least $1 billion
The Tipperary-based company aims to list on the US stock market within the coming months and believes its new drug candidates are worth at least $1 billion